Zum Inhalt springen
Home » Regor Releases Phase 2a Topline Results for RGT-075

Regor Releases Phase 2a Topline Results for RGT-075

Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau.
No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo.
Enrollment opening for its COMO-1 Phase 2b dose-finding study to read out Q4 2025

LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu